Regulatory Affairs and Pharmacovigilance Services in UK
                     Regulatory Affairs and 
Pharmacovigilance 
Services in UK
A strategic compliance guide for pharmaceutical developers and 
medical device manufacturers entering the post-Brexit UK market.
STRATEGIC COMPLIANCE GUIDE
The MHRA: A Standalone 
Global Regulator
Since exiting the EU framework, the MHRA operates as an independent 
regulator with tailored pathways, accelerated access initiatives, and distinct 
post-market surveillance obligations. Success in the UK market demands 
more than replicating EU strategies — it requires local compliance, robust 
scientific data, and vigilant patient safety infrastructure.
Independent Oversight Accelerated Access
Full regulatory autonomy for ILAP and IRP pathways for 
Great Britain faster patient access
Global Standards
Alignment with ICH and international quality benchmarks
The Dual-System Reality: Windsor Framework
Why It Matters
The Windsor Framework creates a dual-system reality. Great 
Britain operates under full MHRA independence, while Northern 
Ireland retains alignment with specific EU single market 
regulations for human medicines.
Distribution, labelling, and pharmacovigilance obligations differ 
materially across the two territories. Dual-region planning is not 
optional — it is a regulatory necessity.
MHRA Authorisation Pathways
The MHRA has prioritised speed without compromising technical rigour. Dossiers must demonstrate high-quality 
scientific evidence, robust CMC data, and complete clinical evaluation summaries.
1 2 3
International Recognition Innovative Licensing and Standard National 
Procedure (IRP) Access Pathway (ILAP) Procedure
Leverages approvals from Accelerated review for products Full MHRA assessment for 
trusted reference authorities to addressing significant unmet products without recognised 
accelerate UK market entry. public health needs. reference approvals.
DOSSIER STRATEGY
Adapting eCTD 
Submissions 
for MHRA
Foreign sponsors face complex hurdles 
adapting international eCTD dossiers to 
MHRA requirements. Module 1 
documentation must be tailored to 
national standards and guidance.
Format electronic files to MHRA- Prepare national Module 1 content Manage direct scientific advice 
specific validation criteria per UK regulatory standards meetings with MHRA assessors
MAH Representation & 
Governance in Great Britain
A Marketing Authorisation Holder for Great Britain must be established 
within the UK or an EEA state. Local operational contacts remain essential 
for regulatory correspondence and post-authorisation obligations.
UK-Based MAH EEA-Based MAH
Direct legal ownership Permitted with designated 
within Great Britain UK operational contacts
MAH Services
Compliance without establishing costly local entities
UK Pharmacovigilance: A Standalone Infrastructure
Beyond Market Access
Securing authorisation is only the first milestone. Post-authorisation monitoring in 
Great Britain requires a pharmacovigilance infrastructure independent of 
EudraVigilance.
• Adverse event reporting via the MHRA Yellow Card scheme
• Localised Pharmacovigilance System Master File (PSMF)
• Continuous signal detection specific to the British population
• Periodic safety update reporting to MHRA
UK QPPV & National Safety Requirements
The MHRA mandates a Qualified Person for Pharmacovigilance residing and operating within the UK or EU/EEA. If 
an EU-QPPV is appointed, a UK-based National Contact Person is also required.
UK-QPPV Option EU-QPPV + UK Contact Continuous Signal Detection
A QPPV residing in the UK satisfies An EU-QPPV may be appointed, but Proactive monitoring of UK-specific safety 
MHRA requirements directly, with no a designated UK National Contact data ensures uninterrupted authority 
additional contact person needed. reporting and patient protection.Person must also be established.
Key Takeaways for UK Market Success
Route Optimisation Dual-Region Planning
Utilise the IRP where applicable to leverage approvals from Account for Windsor Framework obligations when 
trusted reference authorities and reduce review timelines. distributing across Great Britain and Northern Ireland.
Local Safety Governance Dossier Flexibility
Maintain a dedicated UK National Contact Person for PV Prepare Module 1 documentation tailored specifically 
to ensure uninterrupted signal monitoring and reporting. to MHRA regulatory standards and national guidance.
Advancing Operational Excellence
Sustained UK compliance requires an end-to-end operational framework 
supported by expert guidance and real-time intelligence.
Life Science Consulting Regulatory Intelligence
Build resilient market entry strategies Stay ahead of MHRA guidance 
with experienced regulatory partners. changes and global safety alerts 
with actionable, real-time insights.
Lifecycle Management Software
Manage complex submissions, variations, and post-market commitments 
through integrated regulatory platforms.
Partner with DDReg Pharma for UK Regulatory Excellence
Regulatory Affairs Pharmacovigilance
Explore Regulatory Services → Explore PV Services →
Regulatory Intelligence Services Contact-us
Explore regulatory intelligence → Get in Touch →